Product Description
Serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for treatment of psoriatic pruritus in a phase 2, randomized clinical trial (NCT03343639).
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vyne Therapeutics
Company Location: BRIDGEWATER NJ 08807
Company CEO: David Domzalski
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Epidermolysis Bullosa|Pruritus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03836001 | P2 |
Completed |
Epidermolysis Bullosa|Pruritus |
2021-12-06 |